Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  
     
   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List >>>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
   


 

 

 

 

 

 

 

 

 

 


 

 




Testosterone Enanthate
Cas No 315-37-7
 

Testosterone Enanthate Dosage and Administration

Dosage and duration of therapy with Testosterone Enanthate injection, USP will depend on age, sex, diagnosis, patient's response to treatment, and appearance of adverse effects. When properly given, injections of Testosterone Enanthate injection, USP are well tolerated. Care should be taken to inject the preparation deeply into the gluteal muscle following the usual precautions for intramuscular administration. In general, total doses above 400 mg per month are not required because of the prolonged action of the preparation. Injections more frequently than every two weeks are rarely indicated. NOTE: Use of a wet needle or wet syringe may cause the solution to become cloudy; however this does not affect the potency of the material. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Testosterone Enanthate injection, USP is a clear, colorless to pale yellow solution.

Male hypogonadism:


As replacement therapy, i.e., for eunuchism, the suggested dosage is 50 to 400 mg every 2 to 4 weeks.

In males with delayed puberty:

Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose. Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months. X-rays should be taken at appropriate intervals to determine the amount of bone maturation and skeletal development

Palliation of inoperable mammary cancer in women:

A dosage of 200 to 400 mg every 2 to 4 weeks is recommended. Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease.


 

                       
PDF DOWNLOAD      WORD DOCUMENT

Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  
Taj pharmaceuticals API Logo
   Testosterone Categories
TESTOSTERONE PHENYLPROPIONATE
 TESTOSTERONE DECANOATE
 TESTOSTERONE UNDECANOATE
 TESTOSTERONE ENANTHATE
 
SIDE EFFECTS
PRECAUTIONS
ADVERSE REACTIONS
DOSAGE AND ADMINISTRATOR
PREGNANCY WARNING
 TESTOSTERONE ISOCAPROATE
 TESTOSTERONE PROPIOANTE
 More Api at Taj Pharmaceuticals Ltd.

 Alfuzosin

 Oseltamivir Phosphate

 Amlodipine Besylate

 Aripiprazole

 Atorvastatin Calcium

 Candesartan Cilaxetil

 Cefdinir

 Cetirizine Dihydrochloride

 Ciprofloxacin HCl

 Dextromethorphan Base

 Diltiazem HCl

 Domperidone Base

 Domperidone Maleate

 Doxazosin Mesylate

 Duloxetine HCl

 Dutasteride

 Enalapril Maleate

 Esomeprazole Magnesium

 Famotidine

 Fexofenadine HCl

 Fluconazole

 Fluoxetine HCl

 Galantamine HBr

 Ibuprofen
 Caffeine

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

      Investor Relations    Feedback     Contact Worldwide    Sitemap
 

taj group logo
2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.